TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06846281: A Randomized, Open-label, Parallel-group, Non-inferiority Study Comparing Efficacy, Safety, and Tolerability of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis, Foll

Sponsor: Novartis Pharmaceuticals · Phase: PHASE3 · Area: CNS_NEUROLOGY · Target Enrollment: 400 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$661,152

Rescue Site Savings

+$440,768

Unlock Full NCT06846281 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06846281 Rescue Dossier →